Ajmera VH, Cachay E, Ramers C, et al. - Researchers used a double-blind, randomized, controlled trial of patients with HIV-associated nonalcoholic fatty liver disease (NAFLD) to test the effectiveness of aramchol, also known as arachidyl amido cholanoic acid, compared with placebo on improvement in MRI–proton density fat fraction (MRI-PDFF) over 12 weeks. For this investigation, they randomized 50 patients with HIV-associated NAFLD, defined by MRI–proton density fat fraction (PDFF) ≥ 5%, to receive either aramchol 600 mg daily (n = 25) or placebo (n = 25) for 12 weeks. In patients with HIV-associated NAFLD, aramchol, over a 12-week period, did not lessen hepatic fat or change body fat and muscle composition by utilizing MRI-based evaluation. No significant adverse events have occurred.